ClinicalTrials.gg
RecruitingNCT07485829Updated Apr 21, 2026

Zimmer Biomet-RibFix Titan

An observational study in Rib Fracture and Rib Fracture Multiple, sponsored by Zimmer Biomet. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Zimmer Biomet · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
54
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Rib Fractures with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Rib Fractures · United States.

Started
2026
the only one that year
Observational
7 of 48
2 open now
Registered
48th of 48
by date
Lead sponsor
2 of 48
Zimmer Biomet

Among the 48 studies in Rib Fractures with a site in United States, this one is the only one that started in 2026, is one of 7 observational ones, and was the 48th registered.

Rib Fractures

126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.

Browse Rib Fractures studies →

Open to participants now

9 of the 48 studies in Rib Fractures with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rib Fractures studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Rib Fractures with a site in United States, or all of them as a file.
02

Study summary

Prospective, single-center, non-randomized, single-cohort, post-market clinical follow-up study to confirm the safety, performance, and clinical benefits for the use of the RibFix Titan™ system implants and instrumentation) in the fusion, stabilization, and fixation of fractures in the chest wall including rib reconstructive surgical procedures, trauma, or planned osteotomies.

Read the detailed description

Consecutive patients who meet all of the inclusion criteria and none of the exclusion criteria will be eligible for participation in the study, and will be pre-screened for participation in the informed consent process.

The primary objective is the assessment of safety by analyzing reoperation rates related to the RibFix Titan™ at 90 days post-implantation. A reoperation will be considered any additional surgical procedure to revise, adjust, or replace the subject device's components and/or any surgical procedure to manage complications directly caused by the device.

This study is designed to evaluate safety parameters by recording the incidence and frequency of complications and adverse events. Relationship of the events to the implant, instrumentation, and/or procedure through the operative and post-operative follow-up periods shall be specified.

The secondary objectives include functional performance and clinical benefits by clinical evaluation of fracture/osteotomy union and patient reported outcome measures (PROMs). This study will also measure resource utilization in subjects with RibFix Titan™, including intensive care unit (ICU) length of stay, hospital length of stay, and operative time.

Data collection will occur at the following intervals: Pre-operative, Operative, 14-days, 45-days, 90-days, and 1-year post-operatively. Enrollment for the study is anticipated to last approximately 12 months. Allowing for 12 months of follow-up, the total estimated study time to final-patient final-visit will be approximately 24 months.

03

Conditions studied

  • Rib Fracture
  • Rib Fracture Multiple

Browse trials for

Keywords

  • RibFix Titan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will include subjects with rib fractures identified at the point of clinical presentation, including emergency departments, trauma centers, or outpatient healthcare settings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age
  2. Willing and able to sign an Institutional Review Board (IRB) approved Form and able to comply with study requirements, in the Investigator's opinion
  3. Independent of study participation, patient qualifies for fixation, stabilization, and/or fusion of rib fractures or osteotomies of normal and osteoporotic bone with the study device

Exclusion criteria

Exclusion Criteria:

  1. Midline Sternotomy: sternotomy incisions crossing the midline
  2. Active Infection: patients should not have any ongoing infections
  3. Material Sensitivity: where sensitivity to materials is suspected, comprehensive testing should be conducted before implantation
  4. Inability to Adhere to Post-operative Care: Patients must have the ability and willingness to comply with post-operative care instructions, which may not be possible for individuals with certain mental or neurological conditions
  5. Patients not expected to survive the duration of follow-up due to the involvement of trauma situations
  6. Patients with a history of alcohol or substance abuse, as well as vulnerable populations such as prisoners and pregnant women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
54 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Rib Fixation

    Consecutive patients will undergo rib fixation procedure using the RibFix Titan fixation system.

    Device: The RibFix Titan™ device should be used within this arm of the study.

Interventions

  • DeviceThe RibFix Titan™ device should be used within this arm of the study.

    Rib Fixation

06

What researchers measure

Primary outcomes

  1. Evaluation of Patient Safety

    Assessment of safety by analyzing reoperation rates related to the RibFix Titan™ at 90 days post-implantation. A reoperation will be considered any additional surgical procedure to revise, adjust, or replace the subject device's components and/or any surgical procedure to manage complications directly caused by the device.

    Time frame: 90 days

Secondary outcomes

  1. Patient Reported Outcome Measure (PROMIS-Pain Interference 8a)

    8-item questionnaire, completed by the patient, with questions asking the patient to rate how much pain has impacted daily functioning over the past 7 days.

    Time frame: 12 Months

  2. Patient Reported Outcome Measure (PROMIS-Physical Function 10b)

    10-item questionnaire, answered by the patient, with questions asking the patient to rate their level of difficulty performing physical activities.

    Time frame: 12 Months

  3. Patient Reported Outcome Measure (Numeric Pain Rating Scale)

    1-item questionnaire asking the patient to rate their pain on average on a numeric scale, from 0 to 10 where 0 is No Pain and 10 is Worst Imaginable Pain.

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jul 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Mar 2028
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07485829
Lead sponsor
Zimmer Biomet
Collaborators
Riverpoint Medical
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Mar 31, 2026
Primary completion
Jul 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Apr 21, 2026

Study contacts

Megan McKinnie
Contact
megan.mckinnie@zimmerbiomet.com
(919)381-7091
Lynsey Boyle
Contact
(412)552-7111
Hillary Overholser
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion